Published in Verh Dtsch Ges Inn Med on January 01, 1976
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
van der Waals density functional for general geometries. Phys Rev Lett (2004) 3.99
Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med (1990) 3.37
Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol (2000) 3.35
Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med (1989) 3.33
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Identification of streptococcal groups A,B,C, and G by slide co-agglutination of antibody-sensitized protein A-containing staphylococci. J Clin Microbiol (1976) 2.76
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol (2001) 2.69
Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol (1988) 2.35
Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet (1986) 2.12
Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol (1987) 2.09
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum (2001) 2.00
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 1.98
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med (1996) 1.93
Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med (2001) 1.77
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus. J Am Coll Cardiol (1986) 1.74
Dose-effects of 8-methoxypsoralen and UVA in cultured human lymphocytes. Br J Dermatol (1978) 1.64
Cyclosporin for acute dermatomyositis. Lancet (1984) 1.61
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
Heavy metal hazards of Asian traditional remedies. Int J Environ Health Res (2001) 1.61
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum (1999) 1.59
Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum (2000) 1.57
Excimer laser photorefractive keratectomy for hyperopia. J Cataract Refract Surg (1997) 1.57
Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol (1990) 1.57
No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m. Eur Respir J (2009) 1.53
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol (2001) 1.51
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum (1994) 1.51
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum (1992) 1.44
[Corrected normal values for serum ACE by genotyping the deletion-/insertion-polymorphism of the ACE gene]. Pneumologie (2001) 1.42
Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum (1999) 1.42
Head and neck manifestations of Wegener's granulomatosis. Rhinology (2006) 1.41
Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol (1998) 1.39
[The risk profile of low-dose methotrexate in the therapy of chronic polyarthritis]. Dtsch Med Wochenschr (1992) 1.39
Treatment of Wegener's granulomatosis: the view from two non-nephrologists. Nephrol Dial Transplant (1994) 1.38
Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis. Semin Arthritis Rheum (2001) 1.38
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax (2008) 1.35
TAP deficiency syndrome. Clin Exp Immunol (2000) 1.35
Double infection with a resistant and a multidrug-resistant strain of Mycobacterium tuberculosis. Emerg Infect Dis (2000) 1.35
Selective cloning of peanut allergens, including profilin and 2S albumins, by phage display technology. Int Arch Allergy Immunol (1999) 1.34
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (2005) 1.33
Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen. J Immunol Methods (1988) 1.33
Assessment of mycobacterial DNA in cells and tissues of mycobacterial and sarcoid lesions. Am J Respir Crit Care Med (1996) 1.33
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) (2008) 1.32
Cryoglobulinemic vasculitis. Arthritis Rheum (1999) 1.31
Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J Bone Joint Surg Am (1993) 1.31
Wegener's autoantigen decoded. Nature (1990) 1.31
[Antineutrophilic cytoplasmic antibodies (ANCA) in inflammatory rheumatic diseases: immunodiagnostic and immunopathogenetic aspects]. Z Rheumatol (1995) 1.31
Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum (1993) 1.27
Monitoring perioperative changes in distribution of pulmonary ventilation by functional electrical impedance tomography. Acta Anaesthesiol Scand (1998) 1.26
Meningitis caused by Streptococcus suis: case report and review of the literature. Infection (1986) 1.25
CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax (2001) 1.24
Erythromelalgia. Clin Orthop Relat Res (1979) 1.24
Biochemical differences among human and animal streptococci of Lancefield group C or group G. J Med Microbiol (1994) 1.22
Grass group I allergens (beta-expansins) are novel, papain-related proteinases. Eur J Biochem (1999) 1.21
Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification. Two new case reports and follow-up of three previously reported cases. J Bone Joint Surg Am (1994) 1.20
Blount disease (tibia vara): another skeletal disorder associated with childhood obesity. J Pediatr (1982) 1.19
Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol (2003) 1.19
Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood (1993) 1.18
Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest (1991) 1.18
Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J (1997) 1.18
The major birch pollen allergen, Bet v 1, shows ribonuclease activity. Planta (1996) 1.17
Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol (2001) 1.17
Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med (1998) 1.16
Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet (2006) 1.16
[Hypertension and tachycardia in acute intermittent porphyria]. Klin Wochenschr (1970) 1.15
Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med (1997) 1.13
Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol (1996) 1.13
Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J (2003) 1.13
Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol (2000) 1.13
Van der Waals density functional for layered structures. Phys Rev Lett (2003) 1.12
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med (1996) 1.12
Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med (1998) 1.12
Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford) (2001) 1.12
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum (1995) 1.11
Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology (1993) 1.11
Condoms for men, not women. Results of brief promotion programs. Sex Transm Dis (1992) 1.11
Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis (2005) 1.10
Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy (1999) 1.10
MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis (2008) 1.10
Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis (2004) 1.08
Haemolytic activity and action on the surface tension of aqueous solutions of synthetic melittins and their derivatives. Experientia (1971) 1.08
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods (1996) 1.08
Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med (1996) 1.08
Peptidasegram in the differentiation of bacilli species. Pathol Microbiol (Basel) (1966) 1.08
Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) (2004) 1.08
End-expiratory lung impedance change enables bedside monitoring of end-expiratory lung volume change. Intensive Care Med (2002) 1.07
Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax (1997) 1.07
The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann Rheum Dis (2007) 1.06
Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J (2001) 1.06
Different cytokine patterns correlate with the extension of disease in pulmonary tuberculosis. Eur Cytokine Netw (1999) 1.06
Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol (1997) 1.06
Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest (1998) 1.06
[Anticytoplasmic antibodies as serological markers and activity parameters of Wegener's granulomatosis. A prospective study]. Dtsch Med Wochenschr (1988) 1.06